Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Semler Scientific Inc (SMLR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: SMLR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -7.4% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 505.93M USD | Price to earnings Ratio - | 1Y Target Price 71 |
Price to earnings Ratio - | 1Y Target Price 71 | ||
Volume (30-day avg) - | Beta 1.43 | 52 Weeks Range 21.77 - 81.56 | Updated Date 06/29/2025 |
52 Weeks Range 21.77 - 81.56 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -60.69% | Operating Margin (TTM) -15.29% |
Management Effectiveness
Return on Assets (TTM) 4.18% | Return on Equity (TTM) -24.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 592336349 | Price to Sales(TTM) 10.28 |
Enterprise Value 592336349 | Price to Sales(TTM) 10.28 | ||
Enterprise Value to Revenue 12.03 | Enterprise Value to EBITDA 7 | Shares Outstanding 13141100 | Shares Floating 10076783 |
Shares Outstanding 13141100 | Shares Floating 10076783 | ||
Percent Insiders 12.03 | Percent Institutions 50.34 |
Upturn AI SWOT
Semler Scientific Inc
Company Overview
History and Background
Semler Scientific, Inc. was founded in 2007. It focuses on developing, manufacturing, and marketing products that help healthcare providers detect, treat, and manage chronic diseases. They initially focused on cardiovascular disease detection.
Core Business Areas
- PAD Detection: Semler's primary focus is on the detection and management of Peripheral Artery Disease (PAD) through its QuantaFlo technology. This includes sales and ongoing services related to this technology.
- Future Product Development: Semler Scientific invests in researching and developing new diagnostic tools for other chronic conditions. They are looking at potential expansion into new markets.
Leadership and Structure
The company is led by Doug Murphy-Chutorian, MD, Chief Executive Officer. The organizational structure is typical of a small publicly traded company, with functional departments such as Sales, Marketing, R&D, and Finance.
Top Products and Market Share
Key Offerings
- QuantaFlo: QuantaFlo is Semler Scientific's primary product. It's a point-of-care arterial blood flow testing device used to diagnose PAD. It's a non-invasive test that measures blood flow in the lower extremities. Market share data is not readily available, but it competes with traditional ABI (Ankle-Brachial Index) testing and other PAD diagnostic methods. Competitors include companies that manufacture ABI testing devices and larger diagnostic equipment vendors.
Market Dynamics
Industry Overview
The diagnostic testing market is growing, driven by an aging population, increasing prevalence of chronic diseases, and a focus on preventive care. There is a move toward point-of-care testing that provides quick and actionable results.
Positioning
Semler Scientific is positioned as a provider of convenient and cost-effective PAD testing solutions. Their competitive advantage lies in the simplicity and ease of use of the QuantaFlo device, making it suitable for use in physician offices.
Total Addressable Market (TAM)
The estimated total addressable market for PAD diagnostics is several billion dollars annually, considering the prevalence of the disease and the costs associated with managing it. Semler Scientific currently captures a small portion of this TAM, indicating significant growth potential.
Upturn SWOT Analysis
Strengths
- Proprietary QuantaFlo technology
- Strong gross margins
- Focus on point-of-care testing
- Relatively low operating expenses
- High insider ownership
Weaknesses
- Dependence on a single product
- Limited sales and marketing resources compared to larger competitors
- Small company size poses risks of scaling
Opportunities
- Expansion into new markets (e.g., international)
- Development of new diagnostic products
- Partnerships with larger healthcare providers
- Increased awareness of PAD and the benefits of early detection
Threats
- Competition from established diagnostic companies
- Changes in reimbursement policies
- Technological advancements that could render QuantaFlo obsolete
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- MESO
- BC
- AXDX
Competitive Landscape
Semler Scientific competes with larger, more established diagnostic companies. Their advantage is their focus on point-of-care PAD testing and the ease of use of QuantaFlo. Disadvantages include limited resources and dependence on a single product.
Growth Trajectory and Initiatives
Historical Growth: Data currently unavailable
Future Projections: Future growth projections are not available
Recent Initiatives: Semler Scientific is focused on expanding its sales force and increasing market penetration of QuantaFlo.
Summary
Semler Scientific is a company focused on PAD diagnostics with its QuantaFlo product. The company benefits from strong margins and a focused approach. However, its reliance on a single product and smaller size pose risks. Expansion and product diversification are key to future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Third-party financial data providers
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Semler Scientific Inc
Exchange NASDAQ | Headquaters Santa Clara, CA, United States | ||
IPO Launch date 2014-02-21 | CEO, President & Director Dr. Douglas Murphy-Chutorian M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 79 | Website https://www.semlerscientific.com |
Full time employees 79 | Website https://www.semlerscientific.com | ||
Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.